However, after a median duration of 18‒24 months of endocrine therapy, PCa progresses to metastatic castration-resistant prostate cancer (mCRPC), defined as PCa that has reached harmful levels of serum testosterone (<50 ng/dl or 1.7 nmol/L) after an initial continuous ADT therapy, persistently elevated prostate-specific antigen (PSA) levels or imaging on progression, reduced patients' quality of life, and shorter survival 3, 4. The gene discussed is KLK3; the disease is posterior cortical atrophy.